Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.
Key Points
Multiple patent cliffs raise concerns about whether Bristol Myers Squibb can maintain its dividend growth streak.
$3.5 billion in anticipated annual cost savings could help the pharmaceutical company bolster its quarterly payouts.
With over $10.5 billion in cash on hand, Bristol Myers Squibb has a substantial backstop to avoid a dividend cut.
- 10 stocks we like better than Bristol Myers Squibb ›
Among healthcare stocks, Bristol Myers Squibb (NYSE: BMY) has built a solid track record of dividend growth. The pharmaceutical company has increased its quarterly dividends during each of the past 18 years.
The company faces patent expirations for Eliquis and other flagship drugs, raising concerns that it can maintain (let alone grow) the dividend. Resolving the company's "patent cliff" remains a work in progress, but there is one important number that offers reassurances about this blue chip dividend stock's growth prospects.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
The $3.5 billion silver bullet
Right off the bat, it's clear that Bristol Myers Squibb, patent cliff or not, will continue generating the cash flow to sustain its $0.63-per-share quarterly dividend (around $2.52 per share annually). For instance, analyst estimates call for earnings of around $6.31 per share this year. Based on these estimates, the stock has a forward payout ratio of around 40%. That's well below what most consider sustainable levels (around 60% or lower).
A big reason why Bristol Myers Squibb can keep generating enough earnings to cover and grow its dividend is its cost-cutting plans, first announced two years ago. At the time, the company's management said it planned to cut $1.5 billion in annual expenses by 2026.
Management made progress executing this plan in 2025, dubbing its cost-cutting program a "strategic productivity initiative." Even better, the company announced plans to reduce annual expenses by an additional $2 billion by 2027. That's $3.5 billion in total anticipated cost savings.
The $10.5 billion backstop
While $3.5 billion may be the most important number for future dividend growth, another figure could help bolster payouts: Bristol Myers Squibb currently sits on around $10.5 billion in cash and cash equivalents.
With this liquidity serving as a backdrop, Bristol Myers Squibb's dividend (currently paying a 4.5% forward yield) looks safe for now, with room to grow. As uncertainty still weighs on shares, any "better than expected" news about the patent cliff could drive a rally.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 11, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
Recommended Articles
